- Home
- TFPM vs APLS Comparison
TFPM vs APLS Comparison
Compare TFPM & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TFPM
- APLS
- Stock Information
- Founded
- TFPM 2016
- APLS 2009
- Country
- TFPM Canada
- APLS United States
- Employees
- TFPM N/A
- APLS N/A
- Industry
- TFPM Precious Metals
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- TFPM Industrials
- APLS Health Care
- Exchange
- TFPM Nasdaq
- APLS Nasdaq
- Market Cap
- TFPM 3.3B
- APLS 3.3B
- IPO Year
- TFPM N/A
- APLS 2017
- Fundamental
- Price
- TFPM $19.16
- APLS $21.87
- Analyst Decision
- TFPM Strong Buy
- APLS Buy
- Analyst Count
- TFPM 4
- APLS 18
- Target Price
- TFPM $20.50
- APLS $45.53
- AVG Volume (30 Days)
- TFPM 260.4K
- APLS 1.8M
- Earning Date
- TFPM 05-18-2025
- APLS 05-06-2025
- Dividend Yield
- TFPM 1.15%
- APLS N/A
- EPS Growth
- TFPM N/A
- APLS N/A
- EPS
- TFPM N/A
- APLS N/A
- Revenue
- TFPM $268,991,000.00
- APLS $781,367,000.00
- Revenue This Year
- TFPM $12.61
- APLS $12.95
- Revenue Next Year
- TFPM N/A
- APLS $21.35
- P/E Ratio
- TFPM N/A
- APLS N/A
- Revenue Growth
- TFPM 31.84
- APLS 97.02
- 52 Week Low
- TFPM $13.94
- APLS $21.70
- 52 Week High
- TFPM $19.90
- APLS $59.91
- Technical
- Relative Strength Index (RSI)
- TFPM 61.57
- APLS 28.02
- Support Level
- TFPM $19.15
- APLS $23.25
- Resistance Level
- TFPM $19.90
- APLS $24.88
- Average True Range (ATR)
- TFPM 0.48
- APLS 1.01
- MACD
- TFPM -0.01
- APLS -0.03
- Stochastic Oscillator
- TFPM 62.63
- APLS 4.04
About TFPM Triple Flag Precious Metals Corp.
Triple Flag Precious Metals Corp is a precious-metals-focused streaming and royalty company. Its revenues are largely generated from a diversified portfolio of properties in Australia, Canada, Colombia, Cote d'Ivoire, Honduras, Mexico, Mongolia, Peru, South Africa, and the United States.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.